Qiming entities report stakes in VOR BioPharma (NASDAQ: VOR) on Schedule 13G/A

Rhea-AI Filing Summary

VOR BioPharma reports amended ownership disclosures by Qiming-related entities. The filing shows Qiming Venture Partners VIII-HC, L.P. beneficially owns 1,089,767 shares (2.0%), and Qiming Venture Partners VIII Investments, LLC beneficially owns 910,172 shares (1.7%). The filing cites 54,185,582 shares outstanding as of March 31, 2026 for percentage calculations.

The cover pages and incorporated items specify voting and dispositive power figures for each reporting person and include a joint filing agreement incorporated by reference.

Key Figures

Shares outstanding: 54,185,582 shares Qiming Venture Partners VIII-HC holdings: 1,089,767 shares Qiming Venture Partners VIII Investments holdings: 910,172 shares +1 more

4 metrics

Shares outstanding 54,185,582 shares as of March 31, 2026

Qiming Venture Partners VIII-HC holdings 1,089,767 shares reported beneficial ownership (2.0%)

Qiming Venture Partners VIII Investments holdings 910,172 shares reported beneficial ownership (1.7%)

Par value $0.0001 per share Common Stock par value

Key Terms

Schedule 13G/A, Beneficial ownership, Sole Dispositive Power, Joint Filing Agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 ) VOR BIOPHARMA INC. Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership regulatory

"Amount beneficially owned: Row 9 of each Reporting Person's cover page"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 1,089,767.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Joint Filing Agreement regulatory

"Exhibit 99.1 Joint Filing Agreement, dated as of November 5, 2025"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:16 PM Learn about SEC filing dates

FAQ

What does the VOR (VOR) Schedule 13G/A disclose?

It discloses beneficial ownership by Qiming-affiliated entities. The filing lists 1,089,767 shares (2.0%) and 910,172 shares (1.7%), using an outstanding base of 54,185,582 shares as of March 31, 2026.

Which Qiming entities are named in the VOR Schedule 13G/A?

The filing names Qiming Venture Partners VIII-HC, L.P., Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII, LLC, and Qiming GP VIII-HC, LLC, each with Cayman Islands organization and signing individuals as authorized signatories.

How were the ownership percentages for VOR calculated?

Percentages are calculated using 54,185,582 shares outstanding as of March 31, 2026, per issuer-provided information. Each row on the cover page states the sole voting and dispositive powers used to derive those percentages.

Does the Schedule 13G/A indicate control or joint filing arrangements?

Yes. The filing includes a referenced Joint Filing Agreement dated November 5, 2025 and notes relationships among the Qiming entities, including general partner and membership interests that explain aggregated reporting.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

929033207

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 929033207

1

Names of Reporting Persons

Qiming Venture Partners VIII-HC, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,089,767.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,089,767.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,089,767.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Note to Row (11): The percentage is calculated based on 54,185,582 shares of Common Stock outstanding on March 31, 2026, as per the information provided by the Issuer.

SCHEDULE 13G

CUSIP Number(s): 929033207

1

Names of Reporting Persons

Qiming Venture Partners VIII Investments, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 910,172.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 910,172.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

910,172.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Row (11): The percentage is calculated based on 54,185,582 shares of Common Stock outstanding on March 31, 2026, as per the information provided by the Issuer.

SCHEDULE 13G

CUSIP Number(s): 929033207

1

Names of Reporting Persons

Qiming GP VIII, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 910,172.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 910,172.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

910,172.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Row (5) (7) and (9): As of the date of this Schedule 13G/A filing, Qiming GP VIII, LLC is the general partner of Qiming Venture Partners VIII, L.P. and Qiming VIII Strategic Investors Fund, L.P., which are the members of the Qiming Venture Partners VIII Investments, LLC with 99.50% and 0.50% equity interest in Qiming Venture Partners VIII Investments, LLC, respectively. Note to Row (11): The percentage is calculated based on 54,185,582 shares of Common Stock outstanding on March 31, 2026, as per the information provided by the Issuer.

SCHEDULE 13G

CUSIP Number(s): 929033207

1

Names of Reporting Persons

Qiming GP VIII-HC, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,089,767.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,089,767.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,089,767.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: Note to Row (5) (7) and (9): As of the date of this Schedule 13G/A filing, Qiming GP VIII-HC, LLC is the general partner of Qiming Venture Partners VIII-HC, L.P. Note to Row (11): The percentage is calculated based on 54,185,582 shares of Common Stock outstanding on March 31, 2026, as per the information provided by the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VOR BIOPHARMA INC.
(b)	Address of issuer's principal executive offices: 500 Boylston Street, Suite 1350, Boston, MA, 02116.
Item 2.
(a)	Name of person filing: Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"), Qiming Venture Partners VIII-HC, L.P. ("QVP VIIIHC"), Qiming GP VIII, LLC, Qiming GP VIII-HC, LLC (collectively, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The registered address of each of the Reporting Persons is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
(c)	Citizenship: All Reporting Persons are organized in Cayman Islands.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 929033207
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information set forth in Row (5) of the cover page for each of the Reporting Person is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information set forth in Row (6) of the cover page for each of the Reporting Person is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information set forth in Row (7) of the cover page for each of the Reporting Person is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information set forth in Row (8) of the cover page for each of the Reporting Person is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Qiming Venture Partners VIII-HC, L.P.

Signature:	/s/ Holan Lam
Name/Title:	Holan Lam/Authorized Signatory
Date:	05/06/2026

Qiming Venture Partners VIII Investments, LLC

Signature:	/s/ Holan Lam
Name/Title:	Holan Lam/Manager
Date:	05/06/2026

Qiming GP VIII, LLC

Signature:	/s/ Holan Lam
Name/Title:	Holan Lam/Authorized Signatory
Date:	05/06/2026

Qiming GP VIII-HC, LLC

Signature:	/s/ Holan Lam
Name/Title:	Holan Lam/Authorized Signatory
Date:	05/06/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of November 5, 2025 (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on November 5, 2025). https://www.sec.gov/Archives/edgar/data/1817229/000095010325014354/dp237001_exa.htm